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Introduction
Obesity is often associated with the metabolic syndrome,
which includes insulin resistance, dyslipidemia, and
hypertension (1–3). Weight reduction lowers arterial
blood pressure (BP) in obese hypertensive patients, sug-
gesting a close association between energy homeostasis
and BP (2, 4, 5). The mechanisms underlying hyperten-
sion in obesity, however, have not been fully elucidated.
Hyperinsulinemia, frequently associated with obesi-
ty and insulin resistance, also causes excessive insulin
action in a tissue-specific manner in kidney, arterial
walls, and sympathetic nervous system (1–3). This
results in BP elevation through sodium retention, pro-
liferation of VSMCs, and sympathetic activation,
respectively (3, 4, 6). Furthermore, insulin resistance
occurring in vascular endothelial cells may reduce
nitric oxide synthesis, which leads to arterial constric-
tion and BP elevation (7, 8).
A line of evidence has suggested that adipocyte-
derived hypertensive substances such as leptin and
angiotensinogen (AGT) are also involved in the patho-
genesis of obesity-related hypertension (2–4, 9). Leptin,
secreted in excess from enlarged adipose tissue, acti-
vates sympathetic nervous system pathways including
those regulating BP (2–4). The renin-angiotensin sys-
tem (RAS) has also been firmly established as a major
determinant of BP (10, 11). AGT, secreted mainly from
liver and adipose tissue, serves as the unique substrate
of renin and initiates RAS activation (12, 13). Epi-
demiological studies have reported a significant corre-
lation between plasma AGT concentrations and BP or
BMI in some human populations (14, 15). A recent
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Taken together, our findings suggest that overexpression of 11β-HSD1 in fat is sufficient to cause salt-
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study by Massiera et al. has demonstrated that overex-
pression of AGT exclusively in adipose tissue in trans-
genic (Tg) mice results in significant elevation of BP,
suggesting a possible pathophysiologic role of adipose
AGT in obesity-related hypertension (16).
Glucocorticoids play a pivotal role in regulating fat
metabolism, function, and distribution (3, 9, 17).
Patients with Cushing syndrome, a rare disease of sys-
temic glucocorticoid excess caused by pituitary or adre-
nal tumors, develop reversible visceral obesity with
insulin resistance, dyslipidemia, and hypertension
(17–21). However, the pathophysiologic role of gluco-
corticoids in the prevalent forms of obesity and in the
metabolic syndrome has remained obscure because cir-
culating cortisol levels are not elevated in the majority
of obese subjects (22, 23).
Recently, locally enhanced activity of glucocorticoids
in tissues such as adipose tissue and skeletal muscle has
been demonstrated in the metabolic syndrome (24–28).
Activity of 11β-hydroxysteroid dehydrogenase type 1
(11β-HSD1) is significantly increased in fat tissue from
obese humans and rodents, suggesting a role for local
glucocorticoid reamplification in obesity and the meta-
bolic syndrome (25, 26, 28–30). In accordance with this
notion, 11β-HSD1 knockout mice exhibit an apparent
insulin-sensitive phenotype (31, 32) and resist visceral fat
accumulation even when fed a high-fat diet (33). On the
other hand, Tg mice overexpressing 11β-HSD1 in fat tis-
sue (aP2-HSD1 mice) show an increase in enzyme activ-
ity to an extent similar to that seen in obese humans, and
replicate visceral fat accumulation with insulin and lep-
tin resistance and dyslipidemia (34). Thus, the aP2-HSD1
mouse is a unique model for studying the pathophysi-
ology of the human metabolic syndrome.
A major unanswered question is whether aP2-HSD1
mice also develop hypertension, a critical feature of the
metabolic syndrome. Here we show that Tg mice over-
expressing 11β-HSD1 in adipose tissue have hyperten-
sion accompanied by activation of the systemic RAS
and salt sensitivity.
Methods
Animals. Generation of Tg mice overexpressing 11β-HSD1
under the control of the enhancer-promoter region of
the adipocyte fatty acid–binding protein (aP2) gene
(aP2-HSD1 mice) has been reported elsewhere (34). In
these mice, transgene-derived mRNA for rat 11β-HSD1
was expressed specifically in adipose tissue, and due to
Tg regeneration of active glucocorticoid from inactive
forms in adipose tissue, concentrations of corticos-
terone (an active form of glucocorticoid in rodents) in
fat depots was significantly increased. Mice were FVB
congenic strain crosses, WT or hemizygous for the
transgene. Unless otherwise indicated, mice were fed a
chow diet (1% salt; Harlan Teklad Laboratory, Madison,
Wisconsin, USA) and kept on a cycle of 10 hours of light
(0700–1700 hours) and 14 hours of darkness. Male 
aP2-HSD1 mice, 19–27 weeks old, from line 10 (34) and
non-Tg littermates were used in the present study. The
Animal Care and Use Committee at Beth Israel Dea-
coness Medical Center and Harvard Medical School
approved all studies.
Surgical procedures and measurement of blood pressure.
Mice (23–26 weeks of age) were anesthetized with
isoflurane (5% for induction, 2% for maintenance) and
were implanted in the left carotid artery with a catheter
coupled with a sensor and transmitter (TA11PA-C20;
Data Sciences International., St. Paul, Minnesota, USA)
(35, 36). Telemetry signals were received by an antenna
below the cage that relayed the signals to a signal
processor (DataQuest ART Gold version 2.1; Data Sci-
ences International) connected to a Compaq desktop
PC (Compaq Computer Corp., Houston, Texas, USA).
These transmitters allow remote monitoring of BP and
heart rate (HR) in unanesthetized, unrestrained mice.
BP and HR were monitored every minute for 9 days
beginning 1 week after the surgery. Results are
expressed as mean ± SEM of 60 values each hour.
High-salt diet experiments. The aP2-HSD1 mice and
non-Tg littermates 19 weeks of age were given a high-
salt diet containing 8% salt (8% NaCl Diet; Harlan
Teklad Laboratory) for 3 weeks, and BP and HR were
monitored during the course of the experiments.
Pharmacologic blockade of the RAS. To assess the activa-
tion of the RAS in mice, under continuous telemetry
monitoring of mean arterial pressure (MAP) and HR,
the specific angiotensin II receptor AT-1 (AT-1 recep-
tor) antagonist GA0113 (37) (Mitsubishi Pharma
Corp., Yokohama, Japan) was administered orally once
a day (at 1500 hours) for 4 days, and the effect of drug
administration was evaluated at day 5. On examination
of the dose-related effects of GA0113, we found that
the maximal dose that does not lower MAP in non-Tg
mice is 0.1 mg/kg body weight. The long plasma ter-
minal half-life (12.2 hours) and excellent oral bioavail-
ability (94%) of this compound enabled us to give the
drug once a day to mice (37). A previous study using
renal artery–ligated hypertensive rats indicated that
repeated administration of GA0113 at this dose
showed gradually potentiated reduction of elevated BP
that reached a plateau after 4 days of treatment with-
out alteration of HR (37).
Intraperitoneal insulin tolerance testing. After a 6-hour
fast, mice were injected intraperitoneally with 0.75
U/kg body weight insulin (Novolin R; Novo Nordisk
A/S, Bagsvaerd, Denmark) (34). Blood was sampled
from the tail vein before and 15, 30, 60, and 90 minutes
after the injection and blood glucose levels were deter-
mined using a glucometer (One Touch II; LifeScan Inc.,
Milpitas, California, USA).
Hormone assays and mRNA expression. Plasma AGT lev-
els were measured by radioimmunoassay (RIA) as equiv-
alent amounts of angiotensin I (38). Plasma angiotensin
II levels were measured by HPLC coupled with RIA (38).
Plasma aldosterone levels were also measured using an
RIA kit (Diagnostic Products Corp., Los Angeles, Cali-
fornia, USA). Plasma renin concentrations were meas-
ured as reported (39). AGT mRNA levels in mesenteric
Downloaded on June 13, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/17845
adipose depots and liver, and AT-1 receptor mRNA lev-
els in kidney and abdominal aorta, were determined by
quantitative 32P RT-PCR with these primers: AGT (34)
sense (5′-CCTGAAGGCCACCATCTTCT-3′) and antisense
(5′-GATCATTGCGACCTGGGCAG-3′) and AT-1 receptor
(40) sense (5′-CACCTATGTAGATCGCTTC-3′) and anti-
sense (5′-GCACAATCGCCATAATTATCC-3′). The results
were normalized to the signal generated for β-actin and
cyclophilin mRNA’s (Ambion Inc., Austin, Texas, USA).
Histological preparation and in situ hybridization. Kidneys
and adrenal glands were fixed in 10% buffered formalin
and embedded in paraffin wax, and multiple adjacent
4-µm sections were cut and mounted on glass slides.
After dehydration, the sections were stained with H&E.
Sections were examined by an experienced pathologist
(S. Fleming) who was blinded to the genotype. Using
adrenal gland tissue, in situ hybridization for aldos-
terone synthetase and 11β-hydroxylase mRNA’s (41)
was performed using antisense 35S-labeled cRNA
probes. Control procedures using sense probes were per-
formed to confirm specificity. Images of five or six sec-
tions of each gland were quantified autoradiographi-
cally and then statistically evaluated.
Electron microscopy. Kidney tissue for electron
microscopy was immersion-fixed as 1-mm cubes in 4%
glutaraldehyde in carbohydrate buffer. The tissue
blocks were postfixed in osmium tetroxide, washed in
carbohydrate buffer, and dehydrated through a graded
alcohol series. Blocks were embedded in araldite resin.
Ultra-thin sections were cut, mounted on copper grids,
and stained with uranyl acetate and lead citrate. They
were examined on a Phillips CM-12 transmission elec-
tron microscope as previously described (39).
Statistical analyses. Data are expressed as mean ± SEM.
Differences were assessed by unpaired two-tailed t test
or ANOVA where applicable. Differences in MAP and
HR at the different timepoints between two groups
(non-Tg vs. Tg mice or untreated vs. drug-treated mice)
were analyzed by repeated measures ANOVA followed
by the Student t test. (StatView 4.01; Abacus Concepts
Inc., Berkeley, California, USA).
Results
Elevated MAP in aP2-HSD1 mice. As expected (34), at 24
weeks of age, body weight of aP2-HSD1 mice (Tg mice)
was mildly but significantly increased relative to non-
Tg littermates (35.1 ± 2.1 g, n = 7, vs. 30.4 ± 1.6 g, n = 5,
respectively; P < 0.03). When fed ad libitum, blood glu-
cose, plasma insulin, and plasma leptin levels in Tg
mice were significantly elevated (glucose, 172 ± 16 vs.
124 ± 9 mg/dl, P < 0.02; plasma insulin: 792 ± 105 vs.
232 ± 42 pg/ml, P < 0.01; leptin: 6,912 ± 1,012 vs. 
2,190 ± 326 pg/ml, P < 0.01, respectively), indicating the
presence of insulin and leptin resistance in Tg mice.
To explore the cardiovascular consequences of Tg
amplification of glucocorticoid action in fat tissue, BP
and HR were assessed by telemetry. MAP in both non-
Tg (n = 14) and Tg (n = 17) mice at 23 weeks of age
showed a monophasic circadian variation (42) with a
nadir at around 1100–1400 hours and a peak at around
2000–2300 hours (Figure 1a). Throughout the day,
MAP in Tg mice was significantly elevated (by 10–30
mmHg) compared with non-Tg mice (P < 0.04). Notably,
a remarkable rise during the early dark phase was
observed, indicating that MAP elevation in Tg mice is
exaggerated in the active phase. This is reminiscent of a
morning surge that is often observed in human essen-
tial hypertension with multiple metabolic risks (43, 44).
No significant difference in HR was noted between non-
Tg and Tg mice throughout the day (data not shown).
There are several possible mechanisms for the hyperten-
sion associated with the metabolic syndrome. Evidence has
indicated that even in the presence of insulin and leptin
resistance, compensatory hyperinsulinemia and hyper-
leptinemia play pivotal roles in the pathogenesis of obesi-
ty-related hypertension (4, 6, 45). Thus, relative hyperinsu-
linemia and hyperleptinemia in aP2-HSD1 mice are likely
to contribute, at least in part, to BP elevation.
Circulating renin-angiotensin–aldosterone system is activated
in aP2-HSD1 mice. AGT functions as a unique substrate
of renin that is secreted mainly from liver and adipose
tissue (10–12). AGT mRNA in adipocytes is regulated by
nutritional manipulation and upregulated by glucocor-
ticoids (46, 47). Notably, the AGT mRNA level is signifi-
cantly higher in visceral fat than in subcutaneous fat and
is elevated in fat depots from obese humans (14, 15, 48,
49), suggesting that adipose AGT potentially links the
metabolic syndrome with hypertension.
The mRNA expression of AGT in mesenteric fat from
Tg mice was significantly increased compared with
non-Tg mice (372 ± 21, n = 5 vs. 100 ± 2, n = 5, respec-
tively, in arbitrary units). The liver AGT mRNA level
tended to increase in Tg mice, but the difference was
not statistically significant. A comparison of AGT
mRNA levels in mesenteric fat of Tg mice and non-Tg
mice yielded values (in arbitrary units) of 472 ± 49 and
412 ± 28, respectively. Collectively, the plasma AGT
level in Tg mice was also significantly elevated (201 ± 14
nmol/l, n = 7 vs. 159 ± 10, n = 9, respectively; P < 0.03),
further supporting a role for adipose AGT and local
glucocorticoid in the regulation of plasma AGT levels.
These results prompted us to hypothesize that the
activation of the RAS may also be involved in the devel-
opment of high BP in Tg mice. Consistent with this
notion, plasma levels of angiotensin II (Tg: 91.8 ± 5.2
pg/ml, n = 6 vs. non-Tg: 19.8 ± 0.8 pg/ml, n = 3; 
P < 0.001) and aldosterone (Tg: 1,117 ± 142 pmol/l, n = 5
vs. non-Tg: 510 ± 78, n = 5; P < 0.03) were significantly
elevated in Tg mice compared with non-Tg mice, indi-
cating that “substrate excess” can potentiate compo-
nents of the RAS in mice. No appreciable difference
between the two groups was observed in AT-1 receptor
mRNA expression level in kidneys or aortas (data not
shown). It is interesting to note that plasma renin con-
centrations in Tg mice were also increased (1,894 ± 413
ng/ml/h, n = 5) versus non-Tg mice (886 ± 136, n = 5; 
P < 0.03), suggesting impaired negative feedback on cir-
culating RAS by angiotensin II and/or stimulation of
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renin secretion (e.g., by insulin resistance and sympa-
thetic activation) (2, 3, 11, 45). It is unclear at present
whether such observations in Tg mice are consistent
with human pathophysiology. It has been shown that
renin secretion is increased by renal sympathetic activa-
tion (10, 12, 40), and that both hyperinsulinemia and
hyperleptinemia enhance sympathetic nerve activity in
a tissue-specific manner (e.g., kidney, central nervous
system) (2–4). Thus, it is tempting to speculate that in
Tg mice, hyperinsulinemia and hyperleptinemia activate
the sympathetic nervous system and cause subsequent
renin secretion. Further studies are required to clarify
whether such a mechanism is operative in human
hypertension in patients with the metabolic syndrome.
Adrenal 11β-hydroxylase and aldosterone synthetase
are closely related isozymes with distinct roles in glu-
cocorticoid and mineralocorticoid production in adre-
nal cortex (41). 11β-hydroxylase is expressed at higher
levels in the zona fasciculata, catalyzing the final reac-
tion in the production of corticosterone. Aldosterone
synthetase catalyzes the final step in aldosterone
biosynthesis, which is expressed only in the zona
glomerulosa (10, 11). In situ hybridization analyses of
adrenal gland from Tg mice
(n = 3) revealed a significant
increase in aldosterone syn-
thetase mRNA (increase of
31%, P < 0.02) compared
with that in non-Tg mice 
(n = 5), while 11β-hydroxy-
lase mRNA of Tg mice was
decreased (decrease of 38%,
P < 0.02) (Figure 1b). These
results confirm that the cir-
culating RAS was activated
in Tg mice. These data also
suggest that in response to
the adipose overproduction
of glucocorticoid, negative
feedback of the hypothalam-
ic-pituitary-adrenal axis sup-
pressed adrenal glucocorti-
coid production to maintain
the documented normal cir-
culating glucocorticoid lev-
els in Tg mice (34).
To further evaluate the
involvement of RAS activa-
tion in high BP in Tg mice,
the specific AT-1 receptor
antagonist GA0113 was
administered with continu-
ous telemetry monitoring
of MAP and HR. The MAP
profile at day 5 of treatment
demonstrated that elevated
BP in Tg mice (n = 6, 27
weeks of age) was markedly
abrogated by administra-
tion of GA0113 at a low dose (0.1 mg/kg body weight).
This dose did not decrease MAP in non-Tg littermates
(n = 5) (Figure 1c). As the pressure-lowering effect was
exaggerated during dark phase (about 15–30 mmHg
decrease) in Tg mice, the daily MAP profile changed
into a flatter curve without a distinct nadir (Figure 1c).
Taken together, these results indicate that activated
RAS contributes considerably to high BP in Tg mice.
During the course of drug administration, HR
changes were not observed in either group (data not
shown). Telemetry monitoring was continued for 4
days after the final administration. We observed that
MAP returned to the initial values (data not shown),
indicating that the drug intervention did not cause
irreversible tissue damage.
Hypertension in aP2-HSD1 mice is salt-sensitive. Salt sen-
sitivity is a common trait in patients with essential
hypertension, with a prevalence estimated at greater
than 50% (50, 51). Although many factors influence the
BP response to a high-salt diet, the RAS has been
demonstrated to play a central role in this process
(50–52). Compared with salt-resistant subjects, salt-sen-
sitive individuals exhibit a blunted RAS response when
Figure 1
(a) Daily profile of MAP in aP2-HSD1 mice at 23 weeks of age. MAP was monitored closely by teleme-
try transmitters implanted in the left carotid artery. Values are expressed as mean ± SEM of 60 data
points each hour. Throughout the day, MAP in Tg mice (n = 17, filled squares) was significantly ele-
vated (by 10–30 mmHg, P < 0.04) compared with that of non-Tg mice (n = 14, open circles). (b) In
situ hybridization analysis of adrenal glands from aP2-HSD1 mice. Adrenal gland tissue from non-Tg
(n = 5) and Tg mice (n = 3) was hybridized with 35S-labeled cRNA probes for aldosterone synthetase
and 11β-hydroxylase. Images of five or six sections from each gland were quantified and statistically
evaluated (d). Results are expressed as arbitrary units. The ratio of aldosterone synthetase to 
11β-hydroxylase (Aldo/11β) in each sample was also determined. *P < 0.02 versus non-Tg. (c) Effect
of specific AT-1 receptor antagonist GA0113 on MAP in aP2-HSD1 mice at 27 weeks of age. GA0113
was administered orally once per day (0.1 mg/kg body weight, at 1500 hours) for 4 days, and the effect
of drug administration was evaluated by telemetry on day 5. Filled circles, non-Tg (n = 5) initial
(untreated) values; open circles, non-Tg treated; filled squares, Tg (n = 6) initial (untreated); open
squares, Tg treated. *P < 0.05 vs. Tg untreated. Telemetry monitoring was continued for 4 days after
the final administration to observe that MAP in both sets of mice returned to initial values.
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switching from low to high salt intakes (51–54). The
apparent activation of the RAS in aP2-HSD1 mice
prompted us to assess potential salt sensitivity. MAP in
23-week-old non-Tg mice (n = 4) fed a high-salt (8%) diet
for 3 weeks did not significantly increase compared with
initial values when fed a low-salt (1%) chow diet, consis-
tent with previous literature showing that FVB mice are
salt-resistant (55) (Figure 2a, left). On the other hand,
after 3 weeks on a high-salt diet, MAP in Tg mice (n = 5)
was significantly elevated (by 10–20 mmHg) for most of
the day compared with initial values (P < 0.05, except
0700 hours to 0800 hours, 1500 hours to 1600 hours,
and 1800 hours to 2400 hours) (Figure 2a, right).
Notably, BP elevation was exaggerated, especially in the
late dark (100 hours to 500 hours) and light phases (800
hours to 1300 hours) (Figure 2a, right). Thus, the daily
profile of MAP in Tg mice after high salt loading
appeared flatter with a higher nadir, reminiscent of
“non-dipper” type salt-sensitive hypertension in
humans, which is known to be closely associated with
multiple metabolic and cardiovascular risks (56, 57).
Furthermore, 4 days of low-dose administration of
GA0113 (0.1 mg/kg body weight) to Tg mice fed a high-
salt diet markedly abrogated MAP elevation to approx-
imately the levels of non-Tg mice fed a chow diet (Fig-
ure 2b), indicating that the salt-sensitive component in
hypertension of Tg may largely be RAS-dependent.
Histological changes in kidneys of aP2-HSD1 mice. In
25-week-old mice, there was no appreciable differ-
ence in the whole heart weight/body weight ratio
(mg/g), an index of cardiac hypertrophy (58),
between non-Tg (5.8 ± 0.4, n = 8) and Tg (6.0 ± 0.5, 
n = 11) mice. The difference in kidney weight between
non-Tg (246 ± 23 mg) and Tg (287 ± 32 mg) mice
also did not reach statistical significance.
Histological examination of the kidneys of aP2-HSD1
mice (males 24 weeks of age, n = 5) showed evident dis-
tal tubular hypertrophy and hyperplasia starting
immediately proximal to the macula densa (Figure 3, a
and b). The enlarged tubules in Tg mice (Figure 3b)
measured up to 2.5 times the tubular cross-sectional
area of non-Tg mice (Figure 3a). The enlarged tubular
cells in Tg mice exhibited increased cytoplasmic gran-
ularity, most markedly in the basal cytoplasm, with api-
cal nuclear displacement (Figure 3d), while none of
these changes were seen in non-Tg mice (Figure 3c).
Under electron microscopy, increased eosinophilic
granularity corresponded to an increased number of
mitochondria (data not shown). There was also a mod-
est degree of hyperplasia of the juxtaglomerular appa-
ratus in Tg mice (Figure 3f) but not in non-Tg mice
(Figure 3e). In both genotypes, glomeruli, proximal
tubules, medullary thick ascending limb, and blood
vessels were histologically unaltered.
These findings in kidneys of Tg mice are consistent
with chronic high BP, especially salt-sensitive or
angiotensin II–mediated hypertension (59, 60). It is
interesting to note that the features are similar
although less marked than seen in the distal tubule of
mice lacking 11β-HSD type 2 (11β-HSD2–/– mice),
which demonstrate the major features of the syn-
drome of apparent mineralocorticoid excess (SAME)
(39). 11β-HSD2 is a potent dehydrogenase that inacti-
vates glucocorticoid in cells (19, 20). Thus, it is possi-
ble that elevated levels of aldosterone in Tg mice drive
mineralocorticoid receptor activation and may be
responsible, at least in part, for the distal tubular
pathology in Tg mice. Moreover, a recent study has
demonstrated that 11β-HSD2–/– mice have pronounced
endothelial dysfunction causing enhanced norepi-
nephrine-mediated contraction (61). In this context,
further studies addressing endothelial and vascular
function are required to better understand the renal
histological changes observed in aP2-HSD1 mice.
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Figure 2
(a) Effect of high-salt diet on MAP in aP2-HSD1 mice.
The aP2-HSD1 mice and non-Tg littermates at 19 weeks
of age were given a high-salt (8%) diet for 3 weeks. The
graph on the left shows that MAP in non-Tg mice (n = 4)
fed a high-salt diet (filled circles) did not elevate signifi-
cantly compared with the initial values when fed a chow
diet with 1% salt (open circles). The graph at right shows
that MAP in Tg mice fed a high-salt diet (filled squares)
(n = 5) was significantly elevated during most of the day
(except 0700 hours to 0800 hours, 1500 hours to 1600
hours, and 1800 hours to 2400 hours), by 10–20 mmHg
compared with Tg mice fed a normal diet (open
squares). *P < 0.05 vs. Tg mice fed a chow diet. (b)
Effect of the specific AT-1 receptor antagonist GA0113
on MAP in aP2-HSD1 mice fed a high-salt diet. Four
days of low-dose administration of GA0113 (0.1 mg/kg
body weight, which does not lower MAP in non-Tg mice)
to Tg mice fed a high-salt diet (22 weeks of age, n = 4)
(open squares) markedly abrogated MAP elevation to
approximately that of non-Tg mice (filled squares) fed
chow diet. *P < 0.05 vs. Tg mice fed a high-salt diet.
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Discussion
The aP2-HSD1 mouse serves as a unique model to approach the
molecular mechanism of hypertension in the metabolic syn-
drome. The present study demonstrates that aP2-HSD1
mice have hypertension accompanied by features of the
metabolic syndrome, including visceral fat accumula-
tion and insulin and leptin resistance. Our data suggest
that an activated circulating RAS, along with hyperin-
sulinemia and hyperleptinemia, are responsible for
hypertension in the aP2-HSD1 mouse. Previous studies
have shown that RAS blockade is less effective in hyper-
tensive patients with low renin activity (45, 51, 54). On
the other hand, systemic RAS activation may be respon-
sible, at least in part, for the excellent effectiveness of the
AT-1 receptor antagonist on hypertension of aP2-HSD1
mice. In this context, further studies are necessary to
elucidate whether activated RAS is involved in the
pathogenesis of human hypertension in the metabolic
syndrome, as it is in aP2-HSD1 mice.
Although naturally occurring rodent models resem-
bling human metabolic syndrome such as Zucker dia-
betic fatty (ZDF) (62) and obese spontaneous hyperten-
sive (SHROB) rats (63) have been characterized, the
pathophysiologic relationship between hypertension
and the metabolic syndrome in these models remains
incompletely understood. Moreover, it is important to
note that diet-induced obese models, even accompanied
by hyperleptinemia and hyperinsulinemia, do not nec-
essarily have hypertension (64, 65). In this context, aP2-
HSD1 mice are a unique experimental model for study-
ing the pathophysiology of hypertension in a close
analogue of the human metabolic syndrome (Figure 4).
Both animal model studies and clinical investigations
have demonstrated that pharmacologic blockade of the
RAS by angiotensin I–converting enzyme (ACE) inhib-
itors and AT-1 receptor antagonists can ameliorate
whole-body insulin resistance (66–68). It has been shown
that angiotensin II inhibits insulin-stimulated PI3K activ-
ity by interfering with the docking of insulin substrate-1
(IRS-1) with the p85 regulatory subunit of PI3K (69). A
recent in vivo study suggested that impaired insulin sig-
naling located downstream from PI3K activation is
involved in angiotensin II–induced insulin resistance
(70). Collectively, overactivity of the RAS is likely to con-
tribute to insulin resistance in hypertensive individuals
with metabolic complications. Consistent with this
notion, after only 5 days’ administration of an AT-1
receptor antagonist, GA0113 (0.1 mg/kg body weight),
the profile of insulin tolerance in 26-week-old aP2-HSD1
mice (n = 4) was significantly improved compared with
that performed 3 days before the start of treatment. 
Figure 3
Histological examination of the kidneys of aP2-HSD1 mice and non-
Tg littermates (24 weeks of age, male, n = 5 in each group). All are
H&E stained sections photographed at an original magnification of
×400. (a and b) Distal tubular hyperplasia and hypertrophy with an
origin immediately proximal to the macula densa are seen in Tg mice
(b) compared with non-Tg littermates (a). The enlarged tubules in Tg
mice (b, arrows) measured up to 2.5 times the cross-sectional area of
tubules in non-Tg mice (a, arrows). (c and d) Distal tubular hyper-
trophy with increased cytoplasmic granularity and apical nuclear dis-
placement are seen in Tg mice (d, arrows) compared with the normal,
smaller distal tubules in non-Tg mice (c, arrows). (e and f) Moderate
hyperplasia of the juxtaglomerular apparatus (JGA) at the vascular
pole of the glomerulus is found in Tg mice (f) compared with non-Tg
mice (e). White and blue arrows indicate glomeruli and JGAs, respec-
tively. In both genotypes, glomeruli, proximal tubules, medullary thick
ascending limb, and blood vessels were histologically unaltered.
Figure 4
Hypothetical representation of the pathophysiology of hypertension
in aP2-HSD1 mice. Along with causing hyperinsulinemia and hyper-
leptinemia, reamplification of glucocorticoid action in adipose tis-
sue leads to the activation of the circulating RAS and results in
blood pressure elevation. This mouse model may provide a unique
experimental system to better understand the pathophysiology of
hypertension in human metabolic syndrome.
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Percentages of initial value of glucose were: at 30 minutes,
72% ± 3% basal versus 59% ± 6% treated, P < 0.03; 60 min-
utes, 61% ± 4% basal versus 48% ± 3% treated, P < 0.02; 90
minutes, 66% ± 3% basal versus 44% ± 6% treated, P < 0.03.
Serial values in non-Tg mice (n = 6) treated with saline
were 48% ± 3% at 30 minutes, 30% ± 4% at 60 minutes,
and 34% ± 2% at 90 minutes, respectively. These data sug-
gest that circulating RAS activation may contribute to
insulin resistance in aP2-HSD1 mice. Conversely, it is
tempting to speculate that improved insulin sensitivity
caused by RAS blockade may also contribute to the BP
drop in Tg mice.
In summary, the present study demonstrates that 
aP2-HSD1 mice are hypertensive with apparent activa-
tion of the circulating RAS and features of the metabolic
syndrome. The data highlight the potential role of adi-
pose glucocorticoid reactivation in the pathophysiology
of hypertension seen in the metabolic syndrome. The
aP2-HSD1 mouse provides a unique experimental model
in which to better understand the molecular mechanism
of hypertension in the metabolic syndrome. These find-
ings also suggest that drugs that inhibit 11β-HSD1 in
adipose tissue would improve the syndrome’s myriad
pathological features, including hypertension.
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